Improvements in seizures documented earlier in patients with tuberous sclerosis complex (TSC) taking everolimus (Afinitor, Novartis) in the phase 3 EXIST-3 trial have continued during an open-label extension phase of the trial.
US - RxList
Register to myHealthbox
get access to reserved documents
receive targeted news and alerts
bookmark your favourite products
save your latest searches.
Registration is free.
Are you from a Pharmaceutical or Healthcare Company?
myHealthbox can improve the online visibility of your products by as much as 20%.
Contact us to find out more.
myHealthbox™ is a leading provider of health information services to consumers and healthcare professionals.